Print

Idera Pharmaceuticals, Inc. (IDRA) Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients With Psoriasis  
10/15/2012 9:43:07 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases. Idera anticipates top-line data from this study will be available by year-end 2012. TLRs are a class of proteins that play a key role in both inflammation and immunity. Through the inhibition of specific TLRs, Idera’s candidates may represent a novel approach for the treatment of psoriasis, lupus and other autoimmune diseases.